Trial Profile
A study of Omalizumab evaluating response to treatment in Brazilian patients with chronic spontaneous urticaria.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 24 Oct 2016 New trial record